¡Ya estamos en ! Descubre más

CorMedix

CRMD

Capitalización de mercado USD 566 M

7.26 USD

-0.20

2.68%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

7.26

0.00

0%

1 día

-2.68%

5 días

-2.02%

1 mes

-7.16%

3 meses

-12.42%

6 meses

1.82%

En lo que va del año

-40.3%

1 año

-27.98%

5 años

50.94%

10 años

-34.3%

Acerca de: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Empleados: 191

Atención médica Biotecnología

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 61.5%

Neutral 38.5%

Negativo 0%

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer.

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

Zacks Investment Research

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better bang for their buck right now?

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

Zacks Investment Research

Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet

The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8 – 10, 2026.

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

Zacks Investment Research

CorMedix (CRMD) Upgraded to Buy: Here's Why

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CorMedix (CRMD) Upgraded to Buy: Here's Why

Zacks Investment Research

Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade

The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade

Zacks Investment Research

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript

CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript

CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript

CorMedix Q2 Earnings Call Highlights

CorMedix NASDAQ: CRMD reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted EBITDA guidance. The company also said it signed a multiyear commercial supply agreement for DefenCath with an additional large dialysis organization, giving it supply agreements with each of the five largest U.S. dialysis providers.

CorMedix Q2 Earnings Call Highlights

CorMedix Stock Jumps on Strong DefenCath Sales

CorMedix Inc. (NASDAQ:CRMD) shares are rising on Thursday after the company reported strong second-quarter results. The broader market was also slightly higher, with S&P 500 futures up 0.2%.

CorMedix Stock Jumps on Strong DefenCath Sales

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™